





## The Emergence of Zika Virus and Other Arboviruses: Public Health Impacts At Home and Abroad








Michael A. Drebot, PhD Zoonotic Diseases and Special Pathogens National Microbiology Laboratory

AMMI – CACMID Toronto May 4, 2017


PROTECTING AND EMPOWERING CANADIANS TO IMPROVE THEIR HEALTH

## **Presentation Summary:**

- 1. An Introduction to Zika Virus and other Emerging Mosquito-Borne Arboviruses: Ecology, Epidemiology, and Clinical Aspects
- 2. Zika Virus Global Expansion and Outbreak Response
- 3. Zika / Arbovirus Diagnostic Test Complexities and Caveats
- 4. Zika Research: New Diagnostic Platforms, Vector Competence, Surveillance, Models of Pathogenesis, Therapeutics and Vaccines
- 5. Other Arboviruses to Consider During the Canadian Mosquito Season
- \* I have No Conflict of Interests to Disclose




## Mosquito-Borne Pathogens (MBP) Are Significant Contributors to Emerging Infectious Disease – ie. Arboviruses







MBP / Arbovirus associated disease is a concern both for travellers and "stay at home" Canadians



# "Emerging" and Re- EmergingArboviruses of Concern to <u>Travelling</u> Canadians: Zika, Chikungunya, Dengue, Yellow Fever, <u>Murray Valley, Japanese Encephalitis, etc</u>



https://www.ammi.ca/Annual-Conference/20...




<u>2014</u>

## **ZIKA Virus Introduction & History**



### Zika virus (ZIKV):

- Family Flaviviridae, genus Flavivirus
  - Related to Dengue, West Nile, Yellow fever, Japanese encephalitis viruses
- Enveloped virus with +ssRNA genome
- Originally isolated in Uganda from sentinel monkeys in Zika forest in 1947 & from *Aedes africanus* mosquitoes in 1948
- First human cases in early 50's, only sporadic small outbreaks of mild disease
- Primates including humans likely reservoir



- ZIKV from sylvatic to urban settings in Africa and Asia <u>Aedes aegypti</u> strongly suspected as key vector
- Previously assumed that clinical cases -- mild disease, 80% asymptomatic
- Sexual transmission (cases in 2008 US resident, 2013, French Polynesia patient)




- First report of ZIKV outside of Asia/Africa
- Attack rates: 3.6 21.5 / 1.000
- ~ 73% of population developed antibodies
- Only 18% reported symptoms
- Clinical features were mild and no hospital admissions or other complications reported

## **Clinical Features**

Clinical illness is usually mild with acute onset. Symptoms include:

#### ✓ Fever

- ✓ Conjunctivitis (no purulent)
- ✓ Arthralgia
- ✓ Myalgia
- ✓ Headache
- ✓ Asthenia
- ✓ Maculopapular rash
- ✓ Swelling in lower limbs
- ✓ Pruritus (ithc)



Incubation period is 3-12 days

asymptomatic

Approximately 80% of infections are

http://www.cdc.gov/zika/hc-providers/clinicalevaluation.html PROTOCOLO DE VIGILANCIA EN SALUD PUBLICA ENFERMEDAD POR VIRUS ZIKA. INS Colombia. Versión 01 2016-01-21


### Pacific Islands Outbreaks: 2013-2015

- Islands of French Polynesia
- 383 confirmed cases of ZIKV
- 32,000 estimated cases (~12%)
- First reports of Guillain-Barré syndrome in ZIKV patients
- One case of perinatal transmission
- 2014 Cook Islands, Pascua, New Caledonia
- 2015 New Caledonia, Solomon Islands, Fiji, Samoa, Vanuatu
- January 2014 First report of ZIKV in Americas when reported on Easter Island (Chile)



## Significant Burden of ZIKA Disease: 2015-2016-

But additional outbreaks of <u>Dengue, Chikungunya, and recently Yellow Fever !!</u>



## Other Modes of Transmission Confirmed or Suspected


- Sexual transmission (all possible combinations; persistence in sperm)
- Blood products/transfusion



- Virus/RNA detected in urine, saliva & breast milk
- Intrauterine and perinatal infections



## Spectrum of ZIKV Disease Appears to Change in Brazil




- Neurological complications including: Guillain-Barré Syndrome in adults and microcephaly in newborns reported at heightened frequency
- Association with microcephaly prompts WHO to declare ZIKV "Public Health Emergency of International Concern" (February 1 2016)

Microcephaly now observed in other countries, other developmental effects, <u>New Study: infected babies with no apparent microcephaly at birth, head</u> <u>growth deceleration after birth observed, other neuro issues (MMWR,CDC)</u>

Did virus mutate or were "novel" clinical aspects of ZIKV previously not detected ? Perhaps **Both** are Factors ?




### **ZIKV** Phylogenetics



### Initial & Ongoing Canadian Public Health Responses

- 1. <u>Rapid risk assessment for Canadian travelers</u> (sexual partners) including <u>travel advice</u>
- Development of <u>case definitions and guidelines for diagnostic testing</u> (Canadian Public Health Laboratory Network – CPHLN, CATMAT, PHAC)
- 3. <u>Diagnostic testing</u> for ZIKV infection and <u>evaluation of new assays</u> (with provincial labs) and <u>ZIKV research</u>



### Ongoing Impact of a Non-Endemic Virus With Severe Clinical Implications (ZIKV) on Canada:

- Travel related infections
- Estimated the 4+ million Canadians travel annually to affected regions
- Additional travel to Florida (ZIKV endemic?) significantly increases the population of travelling Canadians
- 1% of those pregnant or conceived?
- Possibility of sexual transmission upon return home
- Vector-borne transmission in Canada (endemic, establishment)?

# Who should get tested:

**Recommended:** 


Not currently recommended:


- Any symptomatic traveller returning from an affected region
- Asymptomatic pregnant women with travel history
- Sexual contacts of a confirmed Zika case
- Asymp. men or women with travel history who cannot delay pregnancy for medical reasons (IVF)

There are some caveats !


 Asymptomatic men with travel history to an affected region


## **Current Zika Transmission**






# However, the NML continues to receive large numbers of samples for testing !







## Laboratory Case Definitions for Confirmation of ZIKV Infections

 <u>Detection of ZIKV</u> by <u>PCR</u>, antigen presence (IHC), or viral isolation, Specimens for PCR & Isolation include: serum, urine, CSF, semen, etc.

2. <u>Detection of ZIKV-specific Antibodies</u>


IgM positive (e.g., ELISA) and presence of ZIKV-specific neutralizing antibody using plaque reduction neutralization tests (PRNTs)


OR

In a PRNT assay <u>Zika virus is mixed with</u> <u>a patient's serum sample</u> and added to a cell culture monolayer to see if the patient has antibodies that will neutralize the ability of the virus to infect and kill the cells. Patient's sera is <u>also mixed with dengue virus</u> to compare neutralization titres (dilution of sera)


(PRNT assays, ZIKV vs Dengue titres, see below) in acute and/or convalescent samples

Eg. PRNTs -- Zika 640 Dengue 20/40 (observed in PCR positive patients)






## **Diagnostic Testing**




### Molecular

- Two target real-time <u>RT-PCR</u> specific for ZIKV
- Works best on <u>acute specimens</u>
  - <u>Serum</u>: 10-14 days onset (peak 3-5 days post-onset)
  - <u>Urine</u>: 14 days onset
- <u>Viral Isolation is difficult</u>



### **Neutralization Assay (PRNT)**





### Serological

- IgM capture ELISA
  - Screening assay
  - Sensitive, not specific
  - Fast, 2 days

#### <u>ZIKV PRNT</u>


- Confirmatory assay to detect and titer virus-specific antibodies
- Cross PRNTs performed (ZIKV and DENV)
- Laborious & time consuming (7days)
- Significant serological cross-reactivity amongst flavi's can make interpretations difficult even when PRNTs are used !


Different Cell Lines need to evaluated for test refinements

### Zika virus is a "flavivirus" closely related to West Nile, Dengue, Yellow Fever and other members of this virus genus




Both are transmitted by the same mosquito: *Aedes aegypti* – the "yellow fever mosquito"





In exposed individuals both can induce a set of antibodies that can bind both viruses

Because of this ab cross reactivity a patient's serum from a <u>dengue</u> infection can give a <u>positive result</u> <u>in a standard Zika ELISA test</u>



### **ORIGINAL ANTIGENIC SIN & DECREASED IgM INDUCTION**

<u>Original Antigenic Sin</u>, immune system preferentially utilizes immunological memory based on a previous infection when a second slightly different version of that foreign entity (*e.g.* a virus or bacterium) is encountered.

Ie. <u>Acute exposure to a pathogen initially generates specific Abs / "immune boost"</u> to a distinct but related pathogen (antigen) that the individual was <u>previously</u> exposed to in the past, the <u>immune response to the current infection may be</u> significantly decreased / sub optimal (until later in infection)

--- First described in 1960 - Thomas Francis "On the Doctrine of Original Antigenic Sin" Associated with Influenza, HIV, dengue infections, etc. **Den1** > **Den2**, **† abs to Den1** 

--- <u>suboptimal immune response</u> during secondary infection, <u>decreased IgM</u> (implications for vaccination, immunopathology, & diagnostics)




Antibody Testing Caveats: Significant cross-reaction problems especially for IgM ELISA tests but can also confound interpretation of PRNTs when Secondary Exposures occur

*e.g.*, <u>Classic "original antigenic sin" issues</u> caused by other flavivirus infections (<u>travellers</u>) followed by ZIKV exposure, or previous <u>flavivirus vaccinations</u> (YFV, JEV). <u>Paired samples may help resolve the identity of infecting virus on a neutralization assay (PRNT)</u>


But Not Always !!!! As well flavivirus secondary infections may lead to "Impaired IgM Responses" so screening IgM ELISAs need to be sensitive ! Commercial assays so far lack appropriate sensitivity !

#### Secondary Flavivirus Exposure Case Example:



### **ZIKA Virus IgM ELISA Kit Formats and Evaluations:**

Eg. Euroimmun (NS1), NovaTec (NS1), Diasorin (NS1), In Bios (Env)



**Initial** assessment of **NS1** based assays indicate increased **specificity** for distinguishing between antibodies to related flaviviruses such as ZIKV and DENV.


However, the sensitivity for detecting the presence of IgM in acute samples is decreased as compared to the CDC – NML "in house" IgM ELISAs

"<u>Whole virus</u>" / E based antigens in ELISAs appear to provide required <u>sensitivity</u> but <u>may have decreased specificity</u> characteristics





Combining NS1 IgM & IgG ELISAs increase overall sens, however, some issues with distinguishing current from past infections, cost Multiplex E, NS 1, 5 platforms (MIAs) & avidity measurement "promising" (See Friday Session D 05)

### <u>Combining New Technology with Old !</u> <u>Utilizing Various DIAGNOSTIC FORMATS</u>



"Multiplex" Microsphere / Luminix Platform - Detection of antibodies to Zika proteins (Wong S et al. 2017)






#### Application of New and Higher Throughput Neutralization Assays for Serological Testing

Conventional PRNTs versus neutralization assays employing ZIKV Luciferase Platform


(Shan et al 2017)




Novel **Point of Care** Molecular Detection Platforms for ZIKA, etc. :

Multi-Plex <u>**RT – LAMP**</u> based procedures being developed with SmartPhone monitoring / recording capabilities


Tubes, Reaction Wells and Microfluidic Cassette Variations (Saliva, Blood and Urine matrices).



Priye A et al 2017 Song J et al 2016



# Additional Zika Research




Commercial ELISA, etc. kit evaluations, ---

Models for <u>Pathogenesis</u>, <u>Therapeutics – Vaccines</u>, <u>Studies on Vector Competence</u>, <u>Mosquito Surveillance</u>.



### Zika Virus Tissue Tropism and Vaccine Considerations: Research Models and Experimentation



### From Diamond, 2017

<u>Animal Models</u> Are Essential For Determining Factors Associated With <u>ZIKV</u> <u>Virulence (Fetal, GB, etc.)</u>, Mechanisms of <u>Virus-Host Interaction</u>, and Provide Framework For <u>Design & Efficacy Testing of Therapeutics and Vaccines</u>


<u>MICE</u> --- Various types of immunocompromised mice available including those lacking interferon genes or receptors -- ZIKV strains

<u>Non-Human Primates</u> --- eg. Rhesus – Cynomolgus Macaques Infected with Asian – lineage / outbreak ZIKV strains

<u>Pig Models</u> --- viremia, organ infection immune responses, placental piglet transmission, potential reservoir ? Darbellay et al. 2016



### <u>Current Mouse Model Research Findings:</u> (NML carrying out similar research, manus in prep)



# Lazear et al 2016 \_--- Infected Ifnr1 mice had high viral loads in <u>brain</u>, spinal cord and <u>testes</u>.

<u>Govero et al 2016</u> --- used mouse adapted ZIKV to compare infection and pathology with Dengue

- Persistence in testes with ZIKV not Dengue
- <u>Diminished</u> testosterone and oligospermia, cell death and <u>destruction</u> of seminiferous tubules

Therapeutic Potential

Neurological disease Death <u>Sapparapu et al 2016</u> --- <u>mAbs against ZIKV E</u> protein <u>reduced tissue</u>, plaental and fetal infection & mortality



-





### NHP Models

**Dudley et al 2016** --- rhesus macaques susceptible to Asian Lineage ZIKV present in <u>saliva, urine, and CSF</u>. Non-pregnant animals remain viremic 21 days, <u>Pregnant 57 days</u>! <u>Rechallenge – no viral replication</u>

### (<u>NML co- authors</u>)

**Osuna et al 2016 ---** rhesus and cynomolgus macaques infected with similar results but also detected in <u>brain</u>, <u>semen and vaginal secretions</u>.



#### Vaccines Being Developed / Initial Phase 1, 2 Trials

- 1. Two DNA vaccine candidates (Inovio, NIH) Phase 1 trials, Phase 2 initiated
- 2. Inactivated virus vaccines (Walter Reed Army Research Institute)


3. Live attenuated vaccine platforms using chimeric flavivirus formats (pre M-E)
-- Combined Dengue and Zika LAV formulations may provide utility (Laboratory of Infectious Diseases, NIAID)

4. Attenuated weakened live virus (NIH)

<u>Possible Factors/Concerns Effecting Vaccine Development and Application:</u> ---- "<u>Antigenic Sin"</u>– Pre-existing flavi antibody decreases initial ZIKV immune response

> --- <u>Antibody Dependent Enhancement</u> Zika antibody enhances flavi infection

#### **DNA Vaccine Approach**



DNA Vaccine Utilized To Protect Against ZIKV Testes Damage in Mice (Griffin BD et al 2017)

#### **Antibody and Monoclonal / Polyclonal Based Therapeutics:**

--- Neutralizing human antibodies to ZIKV replication and maternal-fetal transmission & disease in mice (<u>Sapparapu et al 2016, Nature</u>)





Broadly reactive mAb panel from subjects previously infected, cloned hybidomas, possible therapeutic and vaccine design insights




#### Genetic Engineering of Bovines For Generating Therapeutic Antibodies




Tranchromosomal Cows:


- > 30 litres of conc ab
- SAB Biotherapeutics



#### **Trans-Chromosomal Bovine Antibodies**

- Ideal for rapid large scale production
- SAB Biotherapeutics has developed humanized cattle
- The bovine immunoglobulin genes have been knocked out and replace with fully human germ line antibody sequences
- Allows for hyper-immunization, and production of fully human polyclonal antibody to emerging pathogens.







## Persistence of ZIKV in Seminal Fluid

- CDC preliminary studies (CDC-PR, 2017) -
- Significant but <u>limited</u> lingering of virus, majority of infections result in 1-3 month semen persistence.
- However there is evidence of 6 month persistence in rare cases which has guided current public health recommendations.
- UK Study (EID publication) with similar results ----

#### Arbovirus Mutation / Evolution Can Lead To Increased Transmission, Expansion, etc.




## Distribution of Primary ZIKV Vectors in USA – Expansion to Canada ?



#### Possible adaption of vectors to different climates, and/or viral adaption to "new" mosquitoes ?


#### Surveillance for *Aedes Aegypti* and *Aedes Albopictus* In Canada Mosquitoes found in Windsor, Ontario in 2016 ! Risk for Establishment is low, however, continual monitoring is warranted.



#### Vector Competence Studies on Canadian Mosquitos (*Aedes vexans, etc*) Lindsay et al.



Infection through needle inoculation



**Oral** infection



Collection of saliva to assess transmission ?!



## Orally Infected Mosquitoes with Two Strains of ZIKV, Winnipeg, MB, Summer 2016

Species	Number tested	No. infected (% infected)	No. disseminated (% dissem.)	Min. No Saliva Pos. (%)
<u>Ae. vexans</u>	131	4 (3.2)	2 (1.5)	2* (1.5)
Oc. euedes	7	1 (14.3)	0	0
Oc. fitchii	10	0	0	0
Oc. sticticus	29	0	0	0
Cx. tarsalis	11	0	0	0
Cq. perturbans	43	0	0	0

\* Live ZIKV isolated from these saliva samples

## Conclusions on Canadian Vector Competence For ZIKV, Lindsay R et al

- To-date, mosquitoes from southern Manitoba have demonstrated poor competence as vectors for ZIKV
- <u>ZIKV multiplied</u> in the <u>bodies</u> of many of the species that were inoculated
- <u>Small numbers of Ae. vexans successfully transmitted</u> ZIKV under <u>laboratory conditions</u>
- There was no significant difference in rates of transmission between the two strains of ZIKV
- Further studies are required to determine whether climatic conditions in Canada are permissive for local transmission of ZIKV

# Vector control strategies for Zika virus and other arboviruses



### Main components include:

- 1. Entomological surveillance
- 2. Vector control options
  - Measures targeting aquatic stages
  - Measures targeting adult mosquitoes
- 3. Personal protective measures

## **Other Mosquito Pathogens**





#### Mosquito Transmitted Arboviruses Isolated in Canada

Virus Eastern equine encephalitis Western equine encephalitis

St. Louis encephalitis <u>West Nile</u>

California encephalitis <u>Snowshoe hare (SSH)</u> <u>Jamestown Canyon</u>

Trivittatus

<u>Antigenic group</u> Alphavirus Alphavirus

Flavivirus Flavivirus

California-Bunya California-Bunya California-Bunya California-Bunya Disease in humans/animals + humans, + animals + humans, + animals


+ humans, - animals + humans, + animals




+ humans, - animals
+ humans, + animals
+ humans, + animals
- humans, - animals


Seasonal trends are key: Most infections occur late in the summer when virus levels are peaking

However, some arbos such as California serogroup cause infections in late spring – should be part of differential when mosquitoes present











#### Case History (Webster D et al 2017):

On July 23, 2015 a 73 year old male from Grand Manan Island, New Brunswick developed symptoms of fatigue, nausea, fever.

Several days later febrile illness progressed to delirium and increasing confusion- encephalitis Condition further declined – post encephalitic dementia in Jan


Herpes, Bartonella, Borrelia. Anaplasma, Coxiella etc. negative (frequent outdoor activities) Case for "VZ Swap Team, & Dr. Duncan Webster"

### Mosquito-borne disease threats: Atlantic Canada




- Sporadic activity limited to enzootic cycles of transmission of
  - West Nile virus (infected birds, horses in early 2000's, no humans)
  - Eastern equine encephalitis virus (horses, no human cases)
- Greater seasonal exposure to other arboviruses like
   Snowshoe hare virus (SSH), Jamestown canyon virus
   (JCV) and other California serogroup viruses
  - Wide range of vectors, high infection prevalence and typically high rates of human exposure, most infections asymptomatic or only mild course of disease but neuroinvasive cases do occur










Acute Serum Sample Tested For CSG (JCV & SSH) IgM: ELISA negative - equiv






## IgM production delay and Original Antigenic Sin as seen in Dengue & Zika flaviviruses.

When similar virus co circulate at high levels previous exposures or co infections can occur that may confound serological test Interpretations


(Previous Canadian serosurveys indicated 9-10% previous Den exposures)

May also cause issues involving Increased Disease Severity and reduced Vaccine efficacy !





#### **Mosquito Transmitted Arboviruses Isolated in Canada**



**Disease in humans/animals** + humans, + animals + humans, + animals

- animals

- animals

- animals


- animals


+ humans, - animals + humans, + animals



## <u>West Nile Virus</u> continues to be our most important domestic arbovirus in Canada, North America

Average Case Density Value per 100,000 population of West Nile virus disease , by provinces and territories in Canada: 2002-2013






# Culiseta melanura distribution and Eastern Equine Encephalitis Virus



First Non-Imported Case in Canada September, 2016 !!

<u>13 year old, Encephalitis case, Ont</u> <u>high titres in serum, PRNT pos CSF</u>



Collection localities for Culiseta melanura in Canada: • specimens v





<u>Vector - borne / mosquito borne zoonotic diseases</u> continue to be of importance as public health issues for both <u>travelling and non-</u> <u>travelling Canadians.</u>

<u>Mosquito associated pathogens continue to emerge and increase in</u> <u>frequency both in Canada and Internationally</u> and need to part of <u>physicians / health care provider's differential.</u>

National and Global Partnerships Using <u>a "One Health" Approach Are</u> Key For Identifying, Monitoring and Characterizing These Pathogens and Assessing The Risk for Both <u>Preparedness & Response</u>

θĽ:

